Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Astera Labs Prices 19.8M Share IPO at $36/sh

Published 03/20/2024, 05:49 AM
© Reuters.  Astera Labs (ALAB) Prices 19.8M Share IPO at $36/sh

Astera Labs, Inc. (ALAB) today announced the pricing of its initial public offering of 19,800,000 shares of its common stock at a price to the public of $36.00 per share. The offering consists of 16,788,903 shares of common stock offered by Astera Labs and 3,011,097 shares of common stock to be sold by certain of Astera Labs’ existing stockholders.

In addition, the underwriters will have a 30-day option to purchase up to an additional 2,970,000 shares of common stock from Astera Labs at the initial public offering price, less underwriting discounts and commissions. The gross proceeds to Astera Labs from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Astera Labs, are expected to be approximately $604.4 million. Astera Labs will not receive any proceeds from the sale of shares by the selling stockholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “ALAB” on March 20, 2024. The offering is expected to close on March 22, 2024, subject to customary closing conditions.

Morgan Stanley and J.P. Morgan are acting as joint book runners for the offering. Barclays, Deutsche Bank Securities, Evercore ISI and Jefferies are additionally acting as book runners, and Needham & Company, Stifel, Craig-Hallum Capital Group, Roth Capital Partners, Loop Capital Markets and Siebert Williams Shank are acting as co-managers.

The proposed offering will be made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from: Morgan Stanley & Co (NYSE:MS). LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 and J.P. Morgan Securities LLC, Attn: Broadridge Financial Solutions (NYSE:BR), 1155 Long Island Avenue, Edgewood, New York 11717, by toll free telephone at 1-866-803-9204 or by email at prospectus-eq_fi@jpmorganchase.com.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission, and became effective on March 19, 2024. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.